Lv1
92 积分 2026-08-18 加入
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy
1个月前
已完结
The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi
1个月前
已关闭
Axicabtagene ciloleucel versus tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma
1个月前
已完结
The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Session (O010-O170)
1个月前
已完结
R-GemOx与RICE方案二线治疗复发或难治性弥漫大B细胞淋巴瘤的临床对比研究
1个月前
已完结
Plenary Abstracts Session & Oral Presentations
1个月前
已完结
Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP
1个月前
已关闭
Zamtocabtagene Autoleucel (Zamto-Cel), a Tandem CD20-CD19 Directed CAR-T cell Therapy As Second-Line Treatment for relapsed/refractory Large B-cell Lymphoma: Primary analysis of the Randomized, Pivotal DALY 2-EU Study
1个月前
已完结
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma
1个月前
已完结
Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
1个月前
已完结
皖公网安备34019202002308
